Skip to content

Nifedipine

FDA-approved product (capsule, oral), marketed as Adalat, Adalat Cc, Afeditab Cr and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nifedipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Coronary Vasospasm
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nifedipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Non-Invasive Positive Pressure Ventilation Management of High Altitude Pulmonary Edema

    NCT04288219 · start 2020-03-01

    Registered record
    Registry ID
    NCT04288219
    Conditions
    High Altitude Pulmonary Edema; Non-Invasive Positive Pressure Ventilation; Hypoxia
    Interventions
    Non-Invasive Positive Pressure Ventilation; Nifedipine; supplemental oxygen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-03-01
    Completion
    2021-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Altitude Pulmonary Edema; Non-Invasive Positive Pressure Ventilation; Hypoxia
    InterventionNon-Invasive Positive Pressure Ventilation; Nifedipine; supplemental oxygen
    PhaseNot applicable
    Registry statusUnknown
  • Evaluating the Utility of Continuous Positive Airway Pressure in the Treatment of High Altitude Pulmonary Edema

    NCT04186598 · start 2020-01-20

    Registered record
    Registry ID
    NCT04186598
    Conditions
    Continuous Positive Airway Pressure; High Altitude Pulmonary Edema
    Interventions
    CPAP mask system; Nifedipine 30 MG; CPAP mask system without PEEP
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-01-20
    Completion
    2023-09-13
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContinuous Positive Airway Pressure; High Altitude Pulmonary Edema
    InterventionCPAP mask system; Nifedipine 30 MG; CPAP mask system without PEEP
    PhaseNot applicable
    Registry statusCompleted
  • Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial

    NCT03675061 · start 2018-12-11

    Registered record
    Registry ID
    NCT03675061
    Conditions
    Pregnancy Preterm
    Interventions
    Current care; PartoSure Test negative; PartoSure Test positive
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-12-11
    Completion
    2021-02-23
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy Preterm
    InterventionCurrent care; PartoSure Test negative; PartoSure Test positive
    PhaseNot applicable
    Registry statusCompleted
  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting
  • Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa

    NCT03542552 · start 2018-06-01

    Registered record
    Registry ID
    NCT03542552
    Conditions
    Placenta Previa
    Interventions
    Magnesium Sulfate; Nifedipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-06-01
    Completion
    2021-04-30
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlacenta Previa
    InterventionMagnesium Sulfate; Nifedipine
    PhasePhase 3
    Registry statusCompleted
  • Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study

    NCT07043985 · start 2018-01-03

    Registered record
    Registry ID
    NCT07043985
    Conditions
    Tissue Modification After Vit c Injection
    Interventions
    biopsy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-01-03
    Completion
    2025-05-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTissue Modification After Vit c Injection
    Interventionbiopsy
    PhaseNot applicable
    Registry statusCompleted
  • Impedance Cardiography to Decrease the Risk of Preeclampsia

    NCT03245970 · start 2017-04-24

    Registered record
    Registry ID
    NCT03245970
    Conditions
    Chronic Hypertension Complicating Pregnancy (Diagnosis); Preeclampsia
    Interventions
    Labetalol Hydrocholoride 200 mg orally every 12 hours; Nifedipine 60 mg orally daily; Atenolol 25 mg daily
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2017-04-24
    Completion
    2020-02-29
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hypertension Complicating Pregnancy (Diagnosis); Preeclampsia
    InterventionLabetalol Hydrocholoride 200 mg orally every 12 hours; Nifedipine 60 mg orally daily; Atenolol 25 mg daily
    PhaseEarly phase 1
    Registry statusWithdrawn
  • Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets

    NCT03100838 · start 2017-03-20

    Registered record
    Registry ID
    NCT03100838
    Conditions
    Healthy Volunteers
    Interventions
    Nifedipine 60 MG Extended Release Oral Tablet; Nifedipine 60 MG Extended Release Oral Tablet; omeprazole/sodium bicarbonate; SmartPill (TM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-20
    Completion
    2018-04-06
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionNifedipine 60 MG Extended Release Oral Tablet; Nifedipine 60 MG Extended Release Oral Tablet; omeprazole/sodium bicarbonate; SmartPill (TM)
    PhasePhase 1
    Registry statusCompleted
  • The Effect of Zinc, β-carotene, and Vitamin D3 in Preterm Delivery Through Placental MyD88, TRIF, NFkB, and IL-1β

    NCT03005496 · start 2017-01

    Registered record
    Registry ID
    NCT03005496
    Conditions
    PreTerm Birth
    Interventions
    Zinc; Nifedipine; Beta Carotene; Vitamin D3; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2017-06
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreTerm Birth
    InterventionZinc; Nifedipine; Beta Carotene; Vitamin D3 +1 more
    PhasePhase 4
    Registry statusCompleted
  • Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

    NCT03027674 · start 2016-08

    Registered record
    Registry ID
    NCT03027674
    Conditions
    Raynaud Phenomenon Due to Trauma; Raynaud Disease; System; Sclerosis; Lupus Erythematosus, Systemic; Dermatomyositis; Ultrasound Therapy; Complications
    Interventions
    10% nifedipine cream; 5% sildenafil cream
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2016-08
    Completion
    2016-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRaynaud Phenomenon Due to Trauma; Raynaud Disease; System; Sclerosis +4 more
    Intervention10% nifedipine cream; 5% sildenafil cream
    PhaseEarly phase 1
    Registry statusCompleted
  • Genetic Polymorphisms of ABCG2/BCRP on the Transport of Nifedipine to Breast Milk.

    NCT03710395 · start 2015-12-14

    Registered record
    Registry ID
    NCT03710395
    Conditions
    Drug Transporter
    Interventions
    Blood and breast milk sampling; Nifedipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-12-14
    Completion
    2019-10-01
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Transporter
    InterventionBlood and breast milk sampling; Nifedipine
    PhasePhase 4
    Registry statusUnknown
  • Nifedipine Versus Indomethacin in the Treatment of Preterm Labour

    NCT01360034 · start 2015-12

    Registered record
    Registry ID
    NCT01360034
    Conditions
    Obstetric Labor, Premature
    Interventions
    Nifedipine; Indomethacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-12
    Completion
    2016-06
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstetric Labor, Premature
    InterventionNifedipine; Indomethacin
    PhasePhase 3
    Registry statusUnknown
  • Early Vascular Adjustments During Hypertensive Pregnancy

    NCT02531490 · start 2015-01-01

    Registered record
    Registry ID
    NCT02531490
    Conditions
    Hypertension, Pregnancy-Induced; Pre-Eclampsia
    Interventions
    Labetalol; Nifedipine; Methyldopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01-01
    Completion
    2023-04
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pregnancy-Induced; Pre-Eclampsia
    InterventionLabetalol; Nifedipine; Methyldopa
    PhasePhase 4
    Registry statusUnknown
  • Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate

    NCT02337881 · start 2015-01

    Registered record
    Registry ID
    NCT02337881
    Conditions
    Labor Preterm Requiring Hospitalization
    Interventions
    nifedipen; Sildenafil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2016-10
    Enrolment
    227

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLabor Preterm Requiring Hospitalization
    Interventionnifedipen; Sildenafil
    PhasePhase 1
    Registry statusUnknown
  • Early Vascular Adjustments to Prevent Preeclampsia

    NCT04216706 · start 2014-11-01

    Registered record
    Registry ID
    NCT04216706
    Conditions
    Preeclampsia; Small for Gestational Age at Delivery; HELLP Syndrome
    Interventions
    tailored pharmaceutical treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-11-01
    Completion
    2020-03-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreeclampsia; Small for Gestational Age at Delivery; HELLP Syndrome
    Interventiontailored pharmaceutical treatment
    PhaseNot recorded
    Registry statusCompleted